73387-56-1

Upstream product

• 930-36-9 1-methyl-1H-pyrazole 
• 106-38-7 para-bromotoluene 
• 766-97-2 4-n-methylphenylacetylene 
• 1239016-73-9 3-(4-methylphenyl)-N,N-dipropylprop-2-yn-1-amine 
• 60-34-4 methylhydrazine 
• 720702-41-0 (1-methyl-1H-pyrazol-5-yl)boronic acid 

Downstream Products

• 1394034-47-9 2-bromo-1-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]ethanone 
• 1394034-46-8 1-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]ethanone 
• 1394034-48-0 N-{2-methyl-4-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-1H-imidazol-1-yl}acetamide 
• 1394034-49-1 2-methyl-4-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-1H-imidazol-1-amine 
• 1394034-50-4 N-{2-methyl-4-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-1H-imidazol-1-yl}imidoformamide 
• 1394034-51-5 7-methyl-5-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazin-4(3H)-one 
• 1394034-52-6 7-methyl-5-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-(1H-1,2,4-triazol-1-yl)imidazo[5,1-f][1,2,4]triazine 
• 1394033-53-4 4-(azetidin-1-yl)-7-methyl-5[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazine 
• 689250-61-1 1-methyl-5-(p-tolyl)-1H-pyrazole-4-carbaldehyde 
• 1415637-99-8 (4,6-dichloropyrimidin-5-yl)(1-methyl-5-(p-tolyl)-1H-pyrazol-4-yl)methanone 
• 1415638-00-4 (4,6-dichloropyrimidin-5-yI)[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yI]methanone 
• 1415637-38-5 4-(azetidin-1-yl)-1-methyl-3-(1-methyl-5-(p-tolyl)-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1390637-82-7 CYP₃cide 
• 1415638-19-5 {4-chloro-6-[(3S)-3-(piperidin-1-yl)pyrrolidin-1-yl]pyrimidin-5-yl}[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]methanone 

Relevant academic research and scientific papers

Regioselective palladium-catalyzed C–H arylation of 4-alkoxy and 4-thioalkyl pyrazoles

A methodology for the palladium-catalyzed regioselective C–H arylation of electron rich pyrazoles has been developed. New ligands and mild conditions (70–90 °C) have been identified for this transformation. An intramolecular application of the methodology provided a novel synthetic route for the regioselective synthesis of 1,5-dihydroisochromeno[4,3-c]pyrazoles and 1,5-dihydroisothiochromeno[4,3-c]pyrazoles.

One-pot oxidation and rearrangement of propargylamines and in situ pyrazole synthesis

Reported here are procedures for a one-pot oxidation and rearrangement of propargylamines to synthesize enaminones, with supporting mechanistic studies. Also reported are the extended one-pot syntheses of pyrazoles, including celecoxib and various heterocyclic compounds.

Palladium-catalysed direct diarylations of pyrazoles with aryl bromides: A one step access to 4,5-diarylpyrazoles

The palladium-catalysed direct arylation of pyrazoles with aryl halides, using PdCl(C3H5)(dppb)/KOAc catalyst, reveals a similar reactivity of C4 and C5 CH bonds of pyrazoles, whereas the C3 CH bond is almost unreactive, and gives ac

Mild palladium-catalyzed regioselective direct arylation of azoles promoted by tetrabutylammonium acetate

A mild, general, and convenient palladium-catalyzed direct arylation of the 5-position of azoles with aryl bromides, efficiently promoted by tetrabutylammonium acetate, is described. 1-Methylpyrazole, oxazole, and thiazole reacted at 70°C in N,N-dimethyla

PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS

The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.

Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders

The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.

Thermolyses of 1,1-dimethyl-2-pyrazolinium fluoborates - Evidence for spiro--1-aza-1,4,6-octatrienyl cation

Thermolyses of 3-aryl-1,1-dimethyl-2-pyrazolinium fluoborates give an isomeric mixture of 3-aryl-1-methylpyrazole and 5-aryl-1-methylpyrazole as major products in complete contrast to the corresponding acyclic analogs. 2,6-Diaryl-3-methylpyridines were isolated only in trace quantities.The probable reasons for this unique behaviour was explored using semi-empirical calculations, non-kinetic methods and radiolabelling experiments.A pathway was proposed.